We recommend

  1. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study
    Veloxis Pharmaceuticals
  2. One-Year Results of Phase 3, Double-Blind, Randomized Trial in De Novo Kidney Transplant Patients
    Veloxis Pharmaceuticals
  3. Two-Year Results of Phase 3, Double-Blind, Randomized Trial in De Novo Kidney Transplant Patients
    Veloxis Pharmaceuticals

 

  1. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate Release Tacrolimus versus Extended Release Tacrolimus in African American Kidney Transplant Recipients
    Veloxis Pharmaceuticals
  2. Review One-Year Results of Phase 3, Double-Blind, Randomized Trial in De Novo Kidney Transplant Patients
    Veloxis Pharmaceuticals
  3. A Steady-State, Head-to-Head, Pharmacokinetic Comparison: An Open-Label, Randomized, Crossover Study
    Veloxis Pharmaceuticals
Powered by
  • Privacy policy
  • Google Analytics settings
I consent to the use of Google Analytics and related cookies across the TrendMD network (widget, website, blog). Learn more